Sirolimus 2% (DrugBank: Sirolimus)
40 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
2 | 筋萎縮性側索硬化症 | 0 |
6 | パーキンソン病 | 0 |
13 | 多発性硬化症/視神経脊髄炎 | 0 |
15 | 封入体筋炎 | 0 |
17 | 多系統萎縮症 | 0 |
19 | ライソゾーム病 | 0 |
34 | 神経線維腫症 | 0 |
35 | 天疱瘡 | 0 |
36 | 表皮水疱症 | 2 |
46 | 悪性関節リウマチ | 0 |
49 | 全身性エリテマトーデス | 0 |
51 | 全身性強皮症 | 0 |
60 | 再生不良性貧血 | 0 |
61 | 自己免疫性溶血性貧血 | 0 |
62 | 発作性夜間ヘモグロビン尿症 | 0 |
63 | 特発性血小板減少性紫斑病 | 0 |
65 | 原発性免疫不全症候群 | 0 |
66 | IgA腎症 | 0 |
67 | 多発性嚢胞腎 | 0 |
84 | サルコイドーシス | 0 |
85 | 特発性間質性肺炎 | 0 |
86 | 肺動脈性肺高血圧症 | 0 |
89 | リンパ脈管筋腫症 | 0 |
96 | クローン病 | 0 |
98 | 好酸球性消化管疾患 | 0 |
127 | 前頭側頭葉変性症 | 0 |
137 | 限局性皮質異形成 | 0 |
157 | スタージ・ウェーバー症候群 | 0 |
158 | 結節性硬化症 | 0 |
192 | コケイン症候群 | 2 |
222 | 一次性ネフローゼ症候群 | 0 |
256 | 筋型糖原病 | 0 |
277 | リンパ管腫症/ゴーハム病 | 0 |
278 | 巨大リンパ管奇形(頚部顔面病変) | 0 |
279 | 巨大静脈奇形(頚部口腔咽頭びまん性病変) | 0 |
280 | 巨大動静脈奇形(頚部顔面又は四肢病変) | 0 |
281 | クリッペル・トレノネー・ウェーバー症候群 | 0 |
283 | 後天性赤芽球癆 | 0 |
285 | ファンコニ貧血 | 0 |
331 | 特発性多中心性キャッスルマン病 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03016715 (ClinicalTrials.gov) | May 2016 | 9/1/2017 | Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study | A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS) | Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome | Drug: Sirolimus 2%;Drug: Vehicle | Premier Specialists, Australia | NULL | Recruiting | 5 Years | N/A | All | 8 | Phase 2 | Australia |
2 | NCT02960997 (ClinicalTrials.gov) | May 2016 | 15/6/2016 | Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study | A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS) | Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome | Drug: Sirolimus, 2%;Drug: Vehicle | Stanford University | NULL | Active, not recruiting | 4 Years | N/A | All | 8 | Phase 2 | United States |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03016715 (ClinicalTrials.gov) | May 2016 | 9/1/2017 | Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study | A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS) | Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome | Drug: Sirolimus 2%;Drug: Vehicle | Premier Specialists, Australia | NULL | Recruiting | 5 Years | N/A | All | 8 | Phase 2 | Australia |
2 | NCT02960997 (ClinicalTrials.gov) | May 2016 | 15/6/2016 | Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) Study | A Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS) | Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne Syndrome | Drug: Sirolimus, 2%;Drug: Vehicle | Stanford University | NULL | Active, not recruiting | 4 Years | N/A | All | 8 | Phase 2 | United States |